Know Cancer

forgot password

A Phase I Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

Phase 1
18 Years
Not Enrolling
Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma

Thank you

Trial Information

A Phase I Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

- To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose
(MTD) of AS1409 in single and repeated doses.

- To determine biological responses to AS1409, including interferon-γ and IP-10
circulating concentrations.

- To determine preliminary pharmacokinetics of AS1409.

- To determine the immunogenicity of AS1409

- To explore the anti-tumour activity of AS1409.

Inclusion Criteria:

- Be 18 years or older at the time of giving informed consent.

- Histologically confirmed diagnosis of renal cell carcinoma or malignant melanoma.

- If renal cell carcinoma, of clear cell or chromophilic/papillary type, with
metastases at any site (but excluding patients with single bony lesion only).

- If malignant melanoma, unresectable Stage III disease or Stage IV disease, with
metastases at any site (but excluding patients with single bony lesion only)

- Patients with clinically stable CNS metastases may enter who have been treated with
surgery or radiation and who do not require steroid therapy.

- ECOG performance status 0-2.

- Patients who have received prior systemic treatment for their malignancy with
chemotherapeutic or biological therapies may enter, provided treatment was completed
within 4 weeks of study entry.

- Patients who have received prior experimental therapy may enter, provided treatment
was completed within 12 weeks of study entry.

- Have adequate bone marrow function as evidenced by neutrophils >1.5 x109/L and
platelets >100 x109/L.

- Have adequate liver and kidney function, as shown by serum bilirubin ≤1.5x upper
limit of normal for the laboratory; ALT and AST both ≤2x upper limit of normal; and
creatinine ≤1.5x upper limit of normal.

- Have either evaluable or measurable disease (patients entering an ascending dosage
cohort) or measurable disease (patients entering the study after MTD is defined).

- Patients who have failed and or are ineligible for standard first line therapy (in
accordance with individual institutional practice)

Exclusion Criteria:

Patients with any of the following will be excluded from the study:

- Patients at poor medical risk because of non-malignant systemic disease or active

- History of clinically significant autoimmune or predominantly Th1-driven clinical
disorders (such as rheumatoid arthritis, psoriasis, chronic inflammatory bowel
disease, for example), with the exception of autoimmune endocrinopathies now treated
with replacement therapy.

- Diabetic retinopathy.

- Substantive surgery within 4 weeks prior to study entry, or expectation of surgery
during the study period.

- Malignancy other than renal cell carcinoma or malignant melanoma within 5 years of
study entry, except for non-melanoma skin cancer and cervical intraepithelial
neoplasia treated definitively or other cancer from which the patient has been
disease-free for 5 years.

- Concurrent treatment with systemic steroids or with other immunosuppressive

- If female, pregnant or breastfeeding;

- Women of child bearing potential or sexually active males, unless (1) the patient (if
female, or the patient's partner, if male) is surgically sterile or (2) using
adequate contraception (defined as either IUD, oral or depot contraceptive, or
barrier plus spermicide) while receiving study treatment and for at least 6 months
after termination of treatment. Women must be post-menopausal for at least 2 years to
be considered of non-childbearing potential

- Any concurrent medical or psychological condition that would limit the ability of the
patient to provide informed consent or to comply with the obligations of the study.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Tumor assessment

Outcome Time Frame:

6 weeks, response confirmed at 4 weeks

Safety Issue:


Principal Investigator

James Spicer, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Kings College School of Medicine


United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:




Start Date:

January 2008

Completion Date:

April 2009

Related Keywords:

  • Metastatic Renal Cell Carcinoma
  • Metastatic Malignant Melanoma
  • Antibody
  • safety
  • tolerability
  • efficacy
  • metastatic renal cell carcinoma
  • metastatic malignant melanoma
  • Carcinoma
  • Carcinoma, Renal Cell
  • Melanoma